Loading
Life sciences · Review
International Journal of Drug Delivery Technology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Targeted drug delivery systems are rising interest for advanced non-small cell lung cancer (NSCLC) and they are becoming even more prominent when standard chemotherapy or targeted therapies are limited by resistance, toxicity, and variable tumour penetration.Antibody-drug conjugates, albumin-bound chemotherapy, polymeric micelles, liposomal platinum compounds, and nanoparticle-based cytotoxic formulations are implemented to help improve intratumoral drug delivery and minimize systemic side effects.Despite the extensive body of literature describing this approach, their efficacy and safety for NSCLC are still not consistent and need to be systematically assessed.Methods: PRISMA 2020 guidelines were used in the systematic review and meta-analysis.The data set covered a comprehensive search in PubMed/MEDLINE, Embase, Scopus, Web of Science, PsycINFO, Cochrane CENTRAL, ClinicalTrials.gov,WHO ICTRP, and other grey-literature references, from database inception to 2026-07-01.The focus was adults with advanced, recurrent, unresectable, or metastatic NSCLC treated with antibody-drug conjugates, albumin-bound chemotherapy, liposomal cytotoxic, polymeric micelles, or nanoparticle platinum formulations.Objective response rate and grade ≥3 treatment-related adverse events were primary outcome factors.Secondary outcomes were progression-free survival, overall survival, treatment discontinuation, neuropathy, pneumonitis/interstitial lung disease, and platform-specific toxicity.Pooled analyses were computed by random-effects models.Results: From a search framework came 1,482 database records and 146 grey-literature records.A total of 412 duplicates were removed, while 1,216 records were screened, 96 reports were considered eligible for inclusion, and the narrative synthesis was conducted on 22 studies.Based on five comparative studies the illustrative meta-analysis is done.The objective response of targeted drug-delivery platforms is better than conventional comparators (pooled odds ratio 1.59, 95% CI: 1.26-2.01;I² = 34.1%).Albumin-bound paclitaxel had the most established comparative evidence, especially in squamous NSCLC.Antibody-drug conjugates were found to have clinically informative properties in biomarker-selected populations, especially HER2-, HER3-, and TROP2-directed populations, and toxicities that were specific to the platform were associated, and these were pneumonitis/interstitial lung disease, haematological toxicity, stomatitis and ocular events.Pharmacologically, nanoparticle and liposomal chemotherapy platforms were both promising but were based on lower certainty evidence.Conclusion: Targeted drug delivery in NSCLC is an important clinical and biologically rational therapeutic approach.Albumin-bound paclitaxel demonstrates a relatively advanced proof of response improvement and altered toxicity, while antibody-drug conjugates show promising biomarker-driven activity with distinct safety considerations.Further welldesigned comparative trials are needed to compare the nanoparticle and liposomal platforms.Thus, targeted delivery strategies may increase the precision treatment target of NSCLC, although clinical utility is constrained by platform type, biomarker choice, toxicity management, and evidence maturity.